FBRX Stock — Forte Biosciences Inc

Forte Biosciences Inc (FBRX)

Updated August 28, 2026.

FBRX is a Stock. Its deepest 1-year drawdown was 55.9%.

Forte Biosciences is a clinical-stage biopharmaceutical company developing therapeutics for autoimmune and autoimmune-related diseases, with its lead product candidate FB102 in Phase 2 clinical trials for applications including celiac disease, vitiligo, and alopecia areata. The company does not currently distribute dividends. As a pre-revenue clinical-stage biotech company, it may appeal to investors seeking exposure to early-stage drug development rather than current income.

FBRX performance

Returns are updating. FBRX's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 55.9%.

FBRX key facts

Asset type

Stock

Asset class

Equity

Inception date

04/13/2017

Distribution frequency

None

Last close

$76.99 (stale; as of 2026-08-28)

Market cap

$1,634,427,408

Average volume

0.0

Payment date

06/16/2020

Beta

2.645

Payout ratio

0.0%

EPS

$-4.57

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

FBRX risks and drawbacks

The deepest 1-year drawdown on record here is 55.9%.

Who may consider FBRX — and who may not

It is a weaker fit for investors who need monthly cash flow (FBRX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on FBRX

• All tickers starting with F

Tagged: Healthcare.

Frequently asked questions